Compare · AMGN vs SOPH
AMGN vs SOPH
Side-by-side comparison of Amgen Inc. (AMGN) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $187.28B, about 498.8x SOPH ($375.5M).
- SOPH has been more active in the news (23 items in the past 4 weeks vs 3 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Amgen Inc.
- SOPHiA GENETICS SA
- Price
- -
- -
- Market cap
- $187.28B
- $375.5M
- 1M return
- -
- +4.17%
- 1Y return
- -
- +64.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2021
- News (4w)
- 3
- 23
- Recent ratings
- 25
- 13
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest SOPH
- Chief Financial Officer Cardoza George sold $4,164 worth of Ordinary Shares (774 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 310,684 units (SEC Form 4) to satisfy withholding obligation
- President Muken Ross sold $2,270 worth of Ordinary Shares (422 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 680,489 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by SOPHiA GENETICS SA
- Director Cox Troy was granted 19,724 units of Ordinary Shares, increasing direct ownership by 6% to 328,743 units (SEC Form 4)
- Director Ossipow Vincent was granted 19,724 units of Ordinary Shares, increasing direct ownership by 4% to 522,860 units (SEC Form 4)
- Director Hibbs Kathy L was granted 19,724 units of Ordinary Shares, increasing direct ownership by 22% to 109,492 units (SEC Form 4)
- Director Hirsch Didier was granted 19,724 units of Ordinary Shares, increasing direct ownership by 9% to 240,220 units (SEC Form 4)
- Director Cossery Jean-Michel was granted 19,724 units of Ordinary Shares, increasing direct ownership by 11% to 206,212 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting